Nov. 1, 2021– The first drug company to deny 340B drug pricing program discounts to safety-net hospitals, health centers, and clinics saw its U.S. revenues jump 26% in the third quarter of 2021, thanks in part to the higher prices it is charging for diabetes drugs sold to 340B providers. In a public financial report, Eli Lilly said its third-quarter U.S. revenue totaled … [Read more...]
Faces of 340B: Community Pharmacy Partnerships Benefit Patients with Diabetes
Oct. 28, 2021 – Courtney Riddle’s patient was at a family-owned pharmacy in Magnolia, Ark., where she always picked up her medications, including the diabetes drug Jardiance that was helping to control her blood sugar levels. The patient’s out-of-pocket cost typically was $16.43 for a month’s supply, but this time it was much different. The patient received a note that said … [Read more...]